Epigenomics AG: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act]
March 19, 2019 at 04:50 am EDT
Share
DGAP Preliminary announcement financial reports: Epigenomics AG / Preliminary announcement on the disclosure of financial statements
Epigenomics AG: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act]
19.03.2019 / 09:44
Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act] transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
Epigenomics AG hereby announces that the following financial reports shall
be disclosed :
Report: Annual financial report
Date of disclosure / German: March 27, 2019
German: https://www.epigenomics.com/de/news-investoren/finanzberichte/
Report: Annual financial report of the group
Date of disclosure / German: March 27, 2019
Date of disclosure / English: March 27, 2019
German: https://www.epigenomics.com/de/news-investoren/finanzberichte/
English: https://www.epigenomics.com/news-investors/financial-reports/
19.03.2019 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de
Epigenomics AG is a Germany-based molecular diagnostics company focused on blood-based detection, prognosis and monitoring of cancers using deoxyribonucleic acid (DNA) methylation technology. It develops and commercializes blood-based diagnostic products across multiple cancer indications. The Company's main product is Epi proColon, a blood test for colorectal cancer screening. Along with the blood-based tests the Company offers services related to research, product development, regulatory approval and manufacturing of in-vitro diagnostic (IVD) products. It also offers Epi proLung, a blood-based test that detects the presence of lung cancer in blood plasma. The Company is present in Europe and the United States.
Epigenomics AG: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act]
EPIGENOMICS AG 
